Literature DB >> 16024619

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.

David Zagzag1, Balaji Krishnamachary, Herman Yee, Hiroaki Okuyama, Luis Chiriboga, M Aktar Ali, Jonathan Melamed, Gregg L Semenza.   

Abstract

The genetic hallmark of hemangioblastomas and clear cell-renal cell carcinomas (CC-RCCs) is loss-of-function of the von Hippel-Lindau (VHL) tumor suppressor protein. VHL is required for oxygen-dependent degradation of hypoxia-inducible factor-1alpha (HIF-1alpha). In hemangioblastomas and CC-RCCs, HIF-1alpha is constitutively overexpressed leading to increased transcription of HIF-1-regulated genes, including vascular endothelial growth factor (VEGF). Because loss of VHL function is associated with increased expression of the chemokine receptor CXCR4 in CC-RCCs, we investigated the expression of HIF-1alpha, CXCR4, and its ligand stromal cell-derived factor-1alpha (SDF-1alpha) in hemangioblastomas and CC-RCCs. Immunohistochemistry revealed overexpression of both CXCR4 and SDF-1alpha within tumor cells and endothelial cells of hemangioblastomas and CC-RCCs. HIF-1alpha was detected in tumor cell nuclei of both hemangioblastomas and CC-RCCs. A specific ELISA showed that hemangioblastomas and CC-RCCs expressed SDF-1alpha protein at levels that were significantly higher than those found in normal tissue. Analysis of the VHL-null RCC line 786-0 revealed that SDF-1alpha mRNA levels were 100-fold higher than in a subclone transfected with the wild-type VHL gene. Expression of CXCR4 and SDF-1alpha mRNA was significantly decreased in HIF-1alpha-null compared with wild-type mouse embryo fibroblasts (MEFs). ELISA and Western blot studies for SDF-1alpha and CXCR4 protein expression confirmed the RNA findings in RCC lines and MEFs. These results suggest that loss-of-function of a single tumor suppressor gene can up-regulate the expression of both a ligand and its receptor, which may establish an autocrine signaling pathway with important roles in the pathogenesis of hemangioblastoma and CC-RCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024619     DOI: 10.1158/0008-5472.CAN-04-4406

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  84 in total

Review 1.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

2.  Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.

Authors:  Arezoo Rasti; Maryam Abolhasani; Leili Saeednejad Zanjani; Mojgan Asgari; Mitra Mehrazma; Zahra Madjd
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-16       Impact factor: 4.553

3.  Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures.

Authors:  David Zagzag; Mine Esencay; Olga Mendez; Herman Yee; Iva Smirnova; Yuanyuan Huang; Luis Chiriboga; Eugene Lukyanov; Mengling Liu; Elizabeth W Newcomb
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

4.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

5.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Human nephrosclerosis triggers a hypoxia-related glomerulopathy.

Authors:  Matthias A Neusser; Maja T Lindenmeyer; Anton G Moll; Stephan Segerer; Ilka Edenhofer; Kontheari Sen; Daniel P Stiehl; Matthias Kretzler; Hermann-Josef Gröne; Detlef Schlöndorff; Clemens D Cohen
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 7.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 8.  Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.

Authors:  Denis Migliorini; Sven Haller; Doron Merkler; Angela Pugliesi-Rinaldi; Avinash Koka; Karl Schaller; Beatrice Leemann; Pierre-Yves Dietrich
Journal:  CNS Oncol       Date:  2015-10-26

Review 9.  The role of stromal-derived factor-1--CXCR7 axis in development and cancer.

Authors:  Radoslaw B Maksym; Maciej Tarnowski; Katarzyna Grymula; Joanna Tarnowska; Marcin Wysoczynski; Riu Liu; Boguslaw Czerny; Janina Ratajczak; Magda Kucia; Mariusz Z Ratajczak
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

10.  SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium.

Authors:  Rebecca Marlow; Phyllis Strickland; Ji Shin Lee; Xinyan Wu; Milana Pebenito; Mikhail Binnewies; Elizabeth K Le; Angel Moran; Hector Macias; Robert D Cardiff; Saraswati Sukumar; Lindsay Hinck
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.